AWS Health Innovation Podcast

Behind the Mic: A Personal Update and What's Next for Podcast

In this special behind-the-scenes episode, host Alex Merwin steps away from our usual guest interviews to share some important personal news and exciting updates about the podcast's direction. After years of bringing you stories from healthcare innovators and building an incredible community of listeners, Alex has reached a pivotal moment in his own journey - one that will shape the future of the show. In this episode, you'll hear: * A personal announcement about Alex's next chapter as an entrepreneur * Heartfelt gratitude to the community, guests, and team who've made this podcast possible * Exciting news about the podcast's continued mission and what's coming next * Reflections on over 100 episodes of healthcare innovation stories * How the show's impact has inspired Alex's own path as a founder Connect with Alex Merwin on LinkedIn [https://www.linkedin.com/in/alexmerwin/] to follow his entrepreneurial journey. Stay tuned for more stories from the AWS Health Innovation Podcast after a brief break.

#124, From Search Algorithms to Scientific Breakthroughs with Doug Selinger from Plex Research

Learn how Plex Research combines PageRank-style algorithms with AI to navigate the complexity of biomedical data, transforming untapped research potential into validated drug discovery opportunities.

#123, Decoding Immune Cell Behavior to Transform Treatment Discovery with Gregory Vladimer from Graph Therapeutics

The intersection of AI and immunology is revolutionizing how we understand and treat complex immune disorders. In this episode of the AWS Health Innovation Podcast, Mike Tarselli, Specialist Leader for HCLS Data & AI, explores the future of precision immunology with Gregory Vladimer, Scientific Co-Founder & CEO of Graph Therapeutics. Graph's innovative approach combines AI-powered analysis with patient cell behavior to develop targeted therapies for millions affected by immune-mediated diseases. 1. How does one transition from immunology research to leading a TechBio company? * Gregory Vladimer's evolution from bench scientist to CEO reflects the changing landscape of drug discovery leadership, where deep scientific expertise meets technological innovation. 2. What distinguishes TechBio 3.0 from earlier approaches? * Modern TechBio companies like Graph represent a more sophisticated model, combining specialized domain knowledge with strategic tech partnerships to enhance drug discovery capabilities. 3. How does Graph's approach to precision medicine differ? * By leveraging functional perturbation modeling and multi-omics data analysis, Graph applies precision oncology principles to decode and treat complex immune conditions like rheumatoid arthritis and Crohn's disease. 4. What role does AI play in Graph's drug discovery platform? * Advanced machine learning systems analyze complex biological data across multiple endpoints, while maintaining scientific rigor through human-in-the-loop validation processes. 5. What's the long-term vision for immune disease treatment? * Graph focuses on building predictive disease models and a comprehensive target generation engine, prioritizing curative potential over rapid commercialization. Learn more about Graph Therapeutics at https://graphtx.com/ [https://graphtx.com/] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]

#122, Revolutionizing Heart Failure Care Through Non-Invasive Sensing with Filip Peters from Acorai

Heart failure affects over 60 million people worldwide, yet monitoring blood pressure inside the heart remains an invasive, complex procedure. In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Filip Peters, CEO of Acorai, about their groundbreaking non-invasive SAVE Sensor System that combines multiple sensing technologies to measure intracardiac pressures - potentially transforming how we manage heart failure. 1. How did Filip transition from finance to healthcare technology? * Drawing from his background in machine learning and financial technology, Filip identified an opportunity to apply advanced analytics to cardiac monitoring. His transition exemplifies how cross-industry expertise can drive healthcare innovation. 2. What makes the SAVE Sensor System unique? * The system integrates four distinct sensor types - seismic, acoustic, visual, and electrical - creating a comprehensive approach to non-invasive cardiac monitoring. This novel combination enables detailed measurement of intracardiac pressures without invasive procedures. 3. How does Acorai's technology impact patient care? * By enabling frequent, non-invasive pressure monitoring, healthcare providers can track heart failure progression more effectively. This capability supports earlier interventions and more precise treatment adjustments, potentially improving outcomes for millions of patients. 4. What considerations went into the device design? * Acorai prioritized portability and user experience, creating an intuitive interface that integrates seamlessly with existing hospital workflows. This practical approach addresses key adoption barriers in clinical settings. 5. What milestones indicate Acorai's market potential? * The company has expanded operations across six countries and received FDA Breakthrough Device Designation, demonstrating strong market validation and regulatory progress. These achievements reflect growing confidence in Acorai's innovative approach. Learn more about Acorai at https://acorai.com/ [https://acorai.com/] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]

#121, Engineering Better Drugs Through Bacterial Intelligence with Nik Sharma & Mo Alomari from BioCorteX

The complex relationship between bacteria and medication efficacy represents one of medicine's most overlooked frontiers. In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, GenAI Leader for Health & Bio at AWS Startups, speaks with Nik Sharma (CEO and Co-Founder) and Muhannad Alomari (CTO and Co-Founder) of BioCorteX. Their groundbreaking work in computational drug-bacteria interaction analysis is reshaping our understanding of personalized medicine and drug development. 1. What inspired BioCorteX's approach to pharmaceutical development? * People living with diseases cannot wait. Drawing from tried and tested engineering methodology, BioCorteX applies sophisticated engineering principles to transform drug development success rates by exploring the drug-bacteria interactions. This cross-industry innovation demonstrates how established engineering practices can revolutionize pharmaceutical outcomes. 2. What role does evolutionary biology play in BioCorteX's research methodology? * The company's approach is fundamentally built on the fact that mitochondria – the power house of cells – are ex-bacteria. This deep historical connection provides crucial insights into how bacterial interactions influence medication responses across diverse populations. 3. How does BioCorteX manage the complexity of human-bacterial interactions? * Understanding biology is one of the most complex tasks that humanity has ever attempted to tackle , with human bacteria interactions that far exceeds the number of stars in our galaxy. Their proprietary Carbon Mirror technology employs advanced emulation technologies to analyze drug-bacteria relationships at an unprecedented scale. This in-silico approach enables the exploration of complex interactions that traditional laboratory methods simply cannot possibly capture. 4. What makes BioCorteX's data approach unique in pharmaceutical development? * The Carbon Knowledge platform leverages 15 million samples from 165 different geopolitical regions worldwide, enabling highly accurate drug trial outcome predictions. The scale and geographical breadth of this highly curated data help optimize clinical trials and enhance success rates for pharmaceutical companies. 5. How does BioCorteX maintain efficiency with a lean team structure? * Operating with just twelve team members, BioCorteX maintains an strong and radically transparent culture where everyone codes while partnering with major industry players. Their focus on scalable output and revenue generation challenges traditional startup growth models. 6. What does BioCorteX's future in personalized medicine look like? * The recent partnership with Tempus demonstrates BioCorteX's commitment to advancing personalized medicine. Their technology platform is positioned to fundamentally change how pharmaceutical companies approach drug development and patient care particularly when moving assets across regions i.e China to Global. Learn more about BioCorteX at https://BioCorteX.com/ [https://BioCorteX.com/] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]